291 related articles for article (PubMed ID: 27813398)
41. Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis.
Sakai A; Ito M; Tomomitsu T; Tsurukami H; Ikeda S; Fukuda F; Mizunuma H; Inoue T; Saito H; Nakamura T;
Osteoporos Int; 2015 Mar; 26(3):1193-202. PubMed ID: 25592133
[TBL] [Abstract][Full Text] [Related]
42. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
[TBL] [Abstract][Full Text] [Related]
43. Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial.
Greenspan SL; Nelson JB; Trump DL; Resnick NM
Ann Intern Med; 2007 Mar; 146(6):416-24. PubMed ID: 17371886
[TBL] [Abstract][Full Text] [Related]
44. Prevention of glucocorticoid-induced osteoporosis in immunobullous diseases with alendronate: a randomized, double-blind, placebo-controlled study.
Tee SI; Yosipovitch G; Chan YC; Chua SH; Koh ET; Chan YH; Tan SS; Tsou IY; Tan SH
Arch Dermatol; 2012 Mar; 148(3):307-14. PubMed ID: 22105813
[TBL] [Abstract][Full Text] [Related]
45. Denosumab versus alendronate in long-term glucocorticoid users: A 12-month randomized controlled trial.
Mok CC; Ho LY; Leung SMT; Cheung HN; Chen SPL; Ma KM
Bone; 2021 May; 146():115902. PubMed ID: 33631355
[TBL] [Abstract][Full Text] [Related]
46. Effects of a combined alendronate and calcitriol agent (Maxmarvil) on bone metabolism in Korean postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study.
Rhee Y; Kang M; Min Y; Byun D; Chung Y; Ahn C; Baek K; Mok J; Kim D; Kim D; Kim H; Kim Y; Myoung S; Kim D; Lim SK
Osteoporos Int; 2006 Dec; 17(12):1801-7. PubMed ID: 17019520
[TBL] [Abstract][Full Text] [Related]
47. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
[TBL] [Abstract][Full Text] [Related]
48. Alendronate for the treatment of osteoporosis in men.
Orwoll E; Ettinger M; Weiss S; Miller P; Kendler D; Graham J; Adami S; Weber K; Lorenc R; Pietschmann P; Vandormael K; Lombardi A
N Engl J Med; 2000 Aug; 343(9):604-10. PubMed ID: 10979796
[TBL] [Abstract][Full Text] [Related]
49. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
Biermasz NR; Hamdy NA; Pereira AM; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2004 May; 60(5):568-75. PubMed ID: 15104559
[TBL] [Abstract][Full Text] [Related]
50. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
[TBL] [Abstract][Full Text] [Related]
51. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
[TBL] [Abstract][Full Text] [Related]
52. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
53. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
Guaraldi G; Orlando G; Madeddu G; Vescini F; Ventura P; Campostrini S; Mura MS; Parise N; Caudarella R; Esposito R
HIV Clin Trials; 2004; 5(5):269-77. PubMed ID: 15562367
[TBL] [Abstract][Full Text] [Related]
54. Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis.
Jacobs JW; de Nijs RN; Lems WF; Geusens PP; Laan RF; Huisman AM; Algra A; Buskens E; Hofbauer LC; Oostveen AC; Bruyn GA; Dijkmans BA; Bijlsma JW
J Rheumatol; 2007 May; 34(5):1051-7. PubMed ID: 17407214
[TBL] [Abstract][Full Text] [Related]
55. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
56. Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.
Lin T; Wang C; Cai XZ; Zhao X; Shi MM; Ying ZM; Yuan FZ; Guo C; Yan SG
Int J Clin Pract; 2012 Apr; 66(4):399-408. PubMed ID: 22313934
[TBL] [Abstract][Full Text] [Related]
57. Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Parthan A; Kruse M; Yurgin N; Huang J; Viswanathan HN; Taylor D
Appl Health Econ Health Policy; 2013 Oct; 11(5):485-97. PubMed ID: 23868102
[TBL] [Abstract][Full Text] [Related]
58. Follow-up of six patients with neurofibromatosis 1-related osteoporosis treated with alendronate for 23 months.
Heervä E; Huilaja L; Leinonen P; Peltonen S; Peltonen J
Calcif Tissue Int; 2014 Jun; 94(6):608-12. PubMed ID: 24390519
[TBL] [Abstract][Full Text] [Related]
59. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
60. Denosumab for the treatment of osteoporosis: a systematic literature review.
Silva-Fernández L; Rosario MP; Martínez-López JA; Carmona L; Loza E
Reumatol Clin; 2013; 9(1):42-52. PubMed ID: 22947600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]